Bo Lan

13PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 17, 2026
BRCAness-Driven Prognostic Model and Regimen-Specific Therapeutic Implications in Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.

|Aug 07, 2026
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

|Apr 09, 2026
A Novel Sensitive Technique to Detect ESR1 Hotspot Mutations in Liquid Biopsy Using Switch-Blocker-Enhanced Targeted Amplification Coupled With Pyrosequencing.

Yantong Zhou, Wenna Wang, Bo Lan

|Jan 05, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.

Xuenan Peng, Ruixia Song, Ying Fan

|Dec 24, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.

Xiaoyan Qian, Xi Chen, Min Xiao

|Jun 19, 2025
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.

Bo Lan, Dan Lv, Changyuan Guo

Pageof 3

Frequent Collaborators

10 joint publications

Fei Ma

6 joint publications

Qiao Li

3 joint publications

Pin Zhang

3 joint publications

Jiayu Wang